Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that ...
The drug aims to address obesity by enhancing fat loss and controlling appetite through its glucagon-like peptide-1 receptor and glucagon receptor activation. Preclinical studies suggest promising ...